BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arvaniti P, Giannoulis G, Gabeta S, Zachou K, Koukoulis GK, Dalekos GN. Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis. JHEP Rep 2020;2:100123. [PMID: 32671332 DOI: 10.1016/j.jhepr.2020.100123] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Horst AK, Kumashie KG, Neumann K, Diehl L, Tiegs G. Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease. Cell Mol Immunol 2021;18:92-111. [PMID: 33110250 DOI: 10.1038/s41423-020-00568-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
2 Vuerich M, Wang N, Kalbasi A, Graham JJ, Longhi MS. Dysfunctional Immune Regulation in Autoimmune Hepatitis: From Pathogenesis to Novel Therapies. Front Immunol 2021;12:746436. [PMID: 34650567 DOI: 10.3389/fimmu.2021.746436] [Reference Citation Analysis]
3 Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmmune hepatitis. Cell Mol Immunol 2021. [PMID: 34580437 DOI: 10.1038/s41423-021-00768-8] [Reference Citation Analysis]
4 Sirbe C, Simu G, Szabo I, Grama A, Pop TL. Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms. Int J Mol Sci 2021;22:13578. [PMID: 34948375 DOI: 10.3390/ijms222413578] [Reference Citation Analysis]
5 Czaja AJ. Review article: targeting the B cell activation system in autoimmune hepatitis. Aliment Pharmacol Ther 2021;54:902-22. [PMID: 34506662 DOI: 10.1111/apt.16574] [Reference Citation Analysis]
6 Ronca V, Bozward AG, Oo YH. Use of immunosuppression in non-transplant hepatology. Best Pract Res Clin Gastroenterol 2021;54-55:101760. [PMID: 34874849 DOI: 10.1016/j.bpg.2021.101760] [Reference Citation Analysis]
7 Cargill T, Culver EL. The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases. Front Immunol 2021;12:661196. [PMID: 33936097 DOI: 10.3389/fimmu.2021.661196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Biewenga M, Heidt S, Vergunst M, Marijnissen CM, de Man RA, van der Eijk AA, van der Meer AJ, Trouw LA, van Hoek B. B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100460] [Reference Citation Analysis]
9 Schultheiß C, Steinmann S, Lohse AW, Binder M. B cells in autoimmune hepatitis: bystanders or central players? Semin Immunopathol 2022. [PMID: 35488094 DOI: 10.1007/s00281-022-00937-5] [Reference Citation Analysis]
10 Weiler-Normann C, Lohse AW. Autoimmune hepatitis: from immunopathogenesis to diagnostic and therapeutic innovation. Curr Opin Gastroenterol 2021;37:86-90. [PMID: 33315793 DOI: 10.1097/MOG.0000000000000701] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Fasano R, Malerba E, Prete M, Solimando AG, Buonavoglia A, Silvestris N, Leone P, Racanelli V. Impact of Antigen Presentation Mechanisms on Immune Response in Autoimmune Hepatitis. Front Immunol 2022;12:814155. [DOI: 10.3389/fimmu.2021.814155] [Reference Citation Analysis]